Cargando…

Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial

Dietary mycoprotein decreases energy intake in lean individuals. The effects in overweight individuals are unclear, and the mechanisms remain to be elucidated. This study aimed to investigate the effect of mycoprotein on energy intake, appetite regulation, and the metabolic phenotype in overweight a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bottin, Jeanne H., Swann, Jonathan R., Cropp, Eleanor, Chambers, Edward S., Ford, Heather E., Ghatei, Mohammed A., Frost, Gary S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910676/
https://www.ncbi.nlm.nih.gov/pubmed/27198187
http://dx.doi.org/10.1017/S0007114516001872
_version_ 1782438042439516160
author Bottin, Jeanne H.
Swann, Jonathan R.
Cropp, Eleanor
Chambers, Edward S.
Ford, Heather E.
Ghatei, Mohammed A.
Frost, Gary S.
author_facet Bottin, Jeanne H.
Swann, Jonathan R.
Cropp, Eleanor
Chambers, Edward S.
Ford, Heather E.
Ghatei, Mohammed A.
Frost, Gary S.
author_sort Bottin, Jeanne H.
collection PubMed
description Dietary mycoprotein decreases energy intake in lean individuals. The effects in overweight individuals are unclear, and the mechanisms remain to be elucidated. This study aimed to investigate the effect of mycoprotein on energy intake, appetite regulation, and the metabolic phenotype in overweight and obese volunteers. In two randomised-controlled trials, fifty-five volunteers (age: 31 (95 % CI 27, 35) years), BMI: 28·0 (95 % CI 27·3, 28·7) kg/m(2)) consumed a test meal containing low (44 g), medium (88 g) or high (132 g) mycoprotein or isoenergetic chicken meals. Visual analogue scales and blood samples were collected to measure appetite, glucose, insulin, peptide tyrosine-tyrosine (PYY) and glucagon-like peptide-1 (GLP-1). Ad libitum energy intake was assessed after 3 h in part A (n 36). Gastric emptying by the paracetamol method, resting energy expenditure and substrate oxidation were recorded in part B (n 14). Metabonomics was used to compare plasma and urine samples in response to the test meals. Mycoprotein reduced energy intake by 10 % (280 kJ (67 kcal)) compared with chicken at the high content (P=0·009). All mycoprotein meals reduced insulin concentrations compared with chicken (incremental AUC(low) (IAUC(low)): −8 %, IAUC(medium): −12 %, IAUC(high): −21 %, P=0·004). There was no significant difference in glucose, PYY, GLP-1, gastric emptying rate and energy expenditure. Following chicken intake, paracetamol-glucuronide was positively associated with fullness. After mycoprotein, creatinine and the deamination product of isoleucine, α-keto-β-methyl-N-valerate, were inversely related to fullness, whereas the ketone body, β-hydroxybutyrate, was positively associated. In conclusion, mycoprotein reduces energy intake and insulin release in overweight volunteers. The mechanism does not involve changes in PYY and GLP-1. The metabonomics analysis may bring new understanding to the appetite regulatory properties of food.
format Online
Article
Text
id pubmed-4910676
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-49106762016-07-27 Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial Bottin, Jeanne H. Swann, Jonathan R. Cropp, Eleanor Chambers, Edward S. Ford, Heather E. Ghatei, Mohammed A. Frost, Gary S. Br J Nutr Full Papers Dietary mycoprotein decreases energy intake in lean individuals. The effects in overweight individuals are unclear, and the mechanisms remain to be elucidated. This study aimed to investigate the effect of mycoprotein on energy intake, appetite regulation, and the metabolic phenotype in overweight and obese volunteers. In two randomised-controlled trials, fifty-five volunteers (age: 31 (95 % CI 27, 35) years), BMI: 28·0 (95 % CI 27·3, 28·7) kg/m(2)) consumed a test meal containing low (44 g), medium (88 g) or high (132 g) mycoprotein or isoenergetic chicken meals. Visual analogue scales and blood samples were collected to measure appetite, glucose, insulin, peptide tyrosine-tyrosine (PYY) and glucagon-like peptide-1 (GLP-1). Ad libitum energy intake was assessed after 3 h in part A (n 36). Gastric emptying by the paracetamol method, resting energy expenditure and substrate oxidation were recorded in part B (n 14). Metabonomics was used to compare plasma and urine samples in response to the test meals. Mycoprotein reduced energy intake by 10 % (280 kJ (67 kcal)) compared with chicken at the high content (P=0·009). All mycoprotein meals reduced insulin concentrations compared with chicken (incremental AUC(low) (IAUC(low)): −8 %, IAUC(medium): −12 %, IAUC(high): −21 %, P=0·004). There was no significant difference in glucose, PYY, GLP-1, gastric emptying rate and energy expenditure. Following chicken intake, paracetamol-glucuronide was positively associated with fullness. After mycoprotein, creatinine and the deamination product of isoleucine, α-keto-β-methyl-N-valerate, were inversely related to fullness, whereas the ketone body, β-hydroxybutyrate, was positively associated. In conclusion, mycoprotein reduces energy intake and insulin release in overweight volunteers. The mechanism does not involve changes in PYY and GLP-1. The metabonomics analysis may bring new understanding to the appetite regulatory properties of food. Cambridge University Press 2016-07-28 /pmc/articles/PMC4910676/ /pubmed/27198187 http://dx.doi.org/10.1017/S0007114516001872 Text en © The Authors 2016 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Papers
Bottin, Jeanne H.
Swann, Jonathan R.
Cropp, Eleanor
Chambers, Edward S.
Ford, Heather E.
Ghatei, Mohammed A.
Frost, Gary S.
Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
title Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
title_full Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
title_fullStr Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
title_full_unstemmed Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
title_short Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
title_sort mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910676/
https://www.ncbi.nlm.nih.gov/pubmed/27198187
http://dx.doi.org/10.1017/S0007114516001872
work_keys_str_mv AT bottinjeanneh mycoproteinreducesenergyintakeandpostprandialinsulinreleasewithoutalteringglucagonlikepeptide1andpeptidetyrosinetyrosineconcentrationsinhealthyoverweightandobeseadultsarandomisedcontrolledtrial
AT swannjonathanr mycoproteinreducesenergyintakeandpostprandialinsulinreleasewithoutalteringglucagonlikepeptide1andpeptidetyrosinetyrosineconcentrationsinhealthyoverweightandobeseadultsarandomisedcontrolledtrial
AT croppeleanor mycoproteinreducesenergyintakeandpostprandialinsulinreleasewithoutalteringglucagonlikepeptide1andpeptidetyrosinetyrosineconcentrationsinhealthyoverweightandobeseadultsarandomisedcontrolledtrial
AT chambersedwards mycoproteinreducesenergyintakeandpostprandialinsulinreleasewithoutalteringglucagonlikepeptide1andpeptidetyrosinetyrosineconcentrationsinhealthyoverweightandobeseadultsarandomisedcontrolledtrial
AT fordheathere mycoproteinreducesenergyintakeandpostprandialinsulinreleasewithoutalteringglucagonlikepeptide1andpeptidetyrosinetyrosineconcentrationsinhealthyoverweightandobeseadultsarandomisedcontrolledtrial
AT ghateimohammeda mycoproteinreducesenergyintakeandpostprandialinsulinreleasewithoutalteringglucagonlikepeptide1andpeptidetyrosinetyrosineconcentrationsinhealthyoverweightandobeseadultsarandomisedcontrolledtrial
AT frostgarys mycoproteinreducesenergyintakeandpostprandialinsulinreleasewithoutalteringglucagonlikepeptide1andpeptidetyrosinetyrosineconcentrationsinhealthyoverweightandobeseadultsarandomisedcontrolledtrial